Finger RP et al. conducted a systematic literature review and network meta-analysis, finding that brolucizumab provides superior retinal thickness reduction and comparable visual acuity gains with fewer injections compared to other anti-VEGF treatments for neovascular age-related macular degeneration. The gene discussed is VEGFA; the disease is age-related macular degeneration.